Destiny Pharma plc
("Destiny Pharma" or "the Company")
Grant of Options
Brighton, United Kingdom - 4 June 2019 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), announces that it has granted options ("Options") over 335,000 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") (representing 0.76 per cent. of the Company's issued share capital) to certain employees of the Company, including the below Director and PDMR.
| Name | Position | Options Issued | Total Options Held Post Issue |
| Neil Clark | Chief Executive Officer | 200,000 | 544,305 |
| Jesus Gonzales | PDMR | 75,000 | 75,000 |
The Options represent awards under the Destiny Pharma Employee Long Term Incentive Plan 2018 approved by the Company on 25 January 2018 for EMI and non-tax advantage options. The Options have been granted at a price of £0.01 per Ordinary Share, which will vest on the third anniversary of the date of grant and are exercisable for ten years thereafter.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
+44 (0) 20 3727 1000
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0)20 3705 9321
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the WHO and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Neil Clark |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Options over ordinary shares of 1 pence each ("Ordinary Shares") |
| Identification code | DEST GB00BDHSP575 | |
| b) | Nature of the transaction | Grant of Options
|
| c) | Price(s) and volume(s) | 1 pence per Ordinary Share 200,000 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
| e) | Date of the transaction | 4 June 2019 |
| f) | Place of the transaction | London Stock Exchange, AIM Market |
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Jesus Gonzales |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Options over ordinary shares of 1 pence each ("Ordinary Shares") |
| Identification code | DEST GB00BDHSP575 | |
| b) | Nature of the transaction | Grant of Options
|
| c) | Price(s) and volume(s) | 1 pence per Ordinary Share 75,000 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
| e) | Date of the transaction | 4 June 2019 |
| f) | Place of the transaction | London Stock Exchange, AIM Market |